Get the Stockscreener App
15.63
0.76%
-0.12
Gh Research Plc stock is traded at $15.63, with a volume of 144.10K.
It is down -0.76% in the last 24 hours and down -5.84% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$15.75
Open:
$15.72
24h Volume:
144.10K
Relative Volume:
0.41
Market Cap:
$969.52M
Revenue:
-
Net Income/Loss:
$-41.43M
P/E Ratio:
-19.78
EPS:
-0.79
Net Cash Flow:
$-39.97M
1W Performance:
-1.08%
1M Performance:
-5.84%
6M Performance:
+16.73%
1Y Performance:
+42.48%
1-Day Range:
$15.27
$15.74
1-Week Range:
$14.94
$16.03
52-Week Range:
$7.98
$19.51
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
15.63 | 976.96M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.13 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
770.79 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
771.53 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.24 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
322.37 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
How (GHRS) Movements Inform Risk Allocation Models - Stock Traders Daily
Aug Outlook: Should you buy the dip on HTLM2025 Trading Recap & Verified Entry Point Signals - baoquankhu1.vn
Surprises Report: Is GH Research PLC showing insider buyingJuly 2025 Analyst Calls & Expert-Curated Trade Recommendations - baoquankhu1.vn
GH Research PLC (NASDAQ:GHRS) Receives $34.11 Consensus Price Target from Brokerages - Defense World
Is GH Research PLC (1KA) stock at risk of policy regulationJuly 2025 Analyst Calls & Weekly High Conviction Ideas - mfd.ru
GH Research PLC (NASDAQ:GHRS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CenterBook Partners LP Invests $2.38 Million in GH Research PLC $GHRS - MarketBeat
Stock Report: Is DBRG stock trending bullishJuly 2025 Analyst Calls & Consistent Profit Alerts - baoquankhu1.vn
GH Research (GHRS) Projected to Post Earnings on Thursday - Defense World
RBC Capital Cite GH Research PLC's (GHRS) Long-Term Sales Potential Following Psychedelics Symposium - Finviz
RBC Capital Cite GH Research PLC’s (GHRS) Long-Term Sales Potential Following Psychedelics Symposium - Insider Monkey
GH Research PLC Reports Q3 2025 Financial Results - MSN
GH Research (NASDAQ:GHRS) Shares Up 8.8%Should You Buy? - MarketBeat
Trading Systems Reacting to (GHRS) Volatility - Stock Traders Daily
Is GH Research PLC stock forming a cup and handleJuly 2025 PreEarnings & Weekly Chart Analysis and Trade Guides - mfd.ru
GH Research PLC (GHRS) Stock Analysis: Potential Upside of 124.74% and Strong Buy Ratings - DirectorsTalk Interviews
Can GH Research PLC ride the EV waveJuly 2025 Summary & Long-Term Investment Growth Plans - mfd.ru
Fed Meeting: Is GH Research PLC stock forming a cup and handle2025 Major Catalysts & High Conviction Investment Ideas - baoquankhu1.vn
Price Action: Is Vitesse Energy Inc stock technically oversoldJuly 2025 Snapshot & Capital Efficiency Focused Ideas - baoquankhu1.vn
How Gh Research Plc (GHRS) Affects Rotational Strategy Timing - Stock Traders Daily
GH Research stock soars after IND update announcement By Investing.com - Investing.com Nigeria
Dividend Watch: What is the dividend yield of GH Research PLC2025 Volatility Report & Daily Stock Trend Reports - baoquankhu1.vn
GH Research PLC (GHRS) Stock Analysis: A Biotech Gem With Over 100% Upside Potential - DirectorsTalk Interviews
Market Review: Can GH Research PLC ride the EV waveQuarterly Investment Review & Safe Capital Allocation Plans - baoquankhu1.vn
Market Pulse: Is GH Research PLC a turnaround storyJuly 2025 Price Swings & Consistent Income Trade Recommendations - baoquankhu1.vn
GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
A | What are the risks of holding GH Research PLCWeekly Investment Recap & Daily Risk Controlled Trade Plans - mfd.ru
GHRS: RBC Capital Raises Price Target to $40, Maintains 'Outperf - GuruFocus
GH Research (NASDAQ:GHRS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
GH Research stock price target raised to $40 from $33 at RBC Capital - Investing.com India
GH Research (NASDAQ:GHRS) Nasdaq 100 Index Experimental Medicine Pathway - Kalkine Media
(GHRS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
GH Research to Present at RBC Capital Markets Psychedelics Symposium - TipRanks
GH Research (NASDAQ:GHRS) Stock Price Down 7.5%Here's What Happened - MarketBeat
Aug Opening: Can GH Research PLC ride the EV waveWeekly Investment Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
GH Research (GHRS) Is Up 9.1% After FDA Lifts Clinical Hold On GH001 Depression Drug - simplywall.st
Aug Setups: Whats the profit margin of GH Research PLCJuly 2025 Fed Impact & Precise Entry and Exit Recommendations - baoquankhu1.vn
What is the dividend yield of GH Research PLCPortfolio Update Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
CEO Change: Is GH Research PLC a turnaround story2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Is GH Research PLC stock undervalued right now2025 Key Highlights & Weekly High Momentum Picks - bollywoodhelpline.com
Aug Setups: Is GH Research PLC stock supported by strong fundamentalsJuly 2025 Summary & Verified Entry Point Detection - Bộ Nội Vụ
GH Research Showcases Positive GH001 Phase 2b Data in Treatment-Resistant Depression at ACNP 2026 - TipRanks
How FDA’s Lifted Clinical Hold On GH001 At GH Research (GHRS) Has Changed Its Investment Story - Yahoo Finance
Responsive Playbooks and the GHRS Inflection - Stock Traders Daily
EBIT per share of GH Research Plc – FWB:1KA - TradingView — Track All Markets
GH Research PLC (GHRS) Stock Analysis: 109.70% Upside Potential Amid Promising Biotech Innovations - DirectorsTalk Interviews
Wall Street Analysts Think GH Research (GHRS) Could Surge 130.59%: Read This Before Placing a Bet - MSN
Will GH Research PLC (1KA) stock profit from fiscal stimulusStability vs Neutral Overview & lightweight options for faster days - Улправда
Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December - Sahm
Assessing GH Research (GHRS) Valuation After FDA Lifts Clinical Hold On GH001 IND - Sahm
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):